Main Content

You have navigated to this page through:

The last list item is the active (current) page.

Volume 33, 2012

Commentary

A Model of Care for Familial Hypercholesterolaemia:Key Role for Clinical Biochemistry

Clin Biochem Rev 2012:33(i);25-31

*Gerald F Watts,1 David R Sullivan,2 Frank M van Bockxmeer,3 Nicola Poplawski,4 Ian Hamilton-
Craig,5 Peter M Clifton,6 Richard C O’Brien,7 Peter M George,8 John R Burnett,9 for the Familial
Hypercholesterolaemia Australasia Network
1Lipid Disorders Clinic, Metabolic Research Centre and Department of Internal Medicine, Royal Perth Hospital, School of
Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; 2Department of Biochemistry and Lipid
Clinic, Royal Prince Alfred Hospital, University of Sydney, NSW, Australia; 3Core Clinical Pathology & Biochemistry, PathWest
Laboratory Medicine WA, Royal Perth Hospital, University of Western Australia; 4South Australia Clinical Genetics Service,
Genetics and Molecular Pathology Directorate, Women’s & Children’s Hospital, Adelaide, SA, Australia; 5Preventive Cardiology
and Lipid Clinic, Gold Coast Hospital, Griffith University, Qld, Australia; 6Baker IDI Heart and Diabetes Institute, Adelaide,
SA, Australia; 7Department of Medicine, Diabetes and Endocrinology, Austin Hospital, University of Melbourne, Melbourne,
Vic., Australia; 8Biochemistry and Pathology, Canterbury Health Laboratories, Lipid Clinic, Christchurch Hospital, University
of Otago, Christchurch, New Zealand; 9Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Lipid
Disorders Clinic, Royal Perth Hospital, University of Western Australia.
*For correspondence: Winthrop Professor Gerald F Watts, gerald.watts@uwa.edu.au

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma low-density lipoprotein (LDL) cholesterol concentrations and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain unrecognised and those diagnosed remain inadequately treated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory.

More

View Full Text
cross-reference author(s): Gerald F Watts, David R Sullivan, Frank M van Bockxmeer, Nicola Poplawski, Ian Hamilton-Craig, Peter M Clifton, Richard C O'Brien, Peter M George, John R Burnett, for the Familial Hypercholesterolaemia Australasia Network

« Return to Volume 33, 2012 Index

Extra Information


Pay Your Bill

End of Document